within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX02_Lysozyme;
model Lysozyme 
   extends Pharmacolibrary.Drugs.ATC.J.J05AX02;

  annotation(Documentation(
    info ="<html><body><p>Lysozyme is a naturally occurring enzyme found in bodily secretions such as saliva, tears, and mucus, where it acts as part of the innate immune system by breaking down the cell walls of bacteria. Pharmaceutically, it has been used for its mild antibacterial and anti-inflammatory actions, but it is not widely approved as a stand-alone systemic drug in modern therapy and is rarely used in clinical practice today, though it may still be found in lozenges and topical products in some countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic (PK) model parameters were identified for systemic administration of lysozyme. PK parameters therefore estimated based on typical properties of similar low-molecular weight proteins and available preclinical evidence.</p><h4>References</h4><ol><li><p>Nagai, J, et al., &amp; Takano, M (2002). Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney. <i>The Journal of pharmacy and pharmacology</i> 54(11) 1491–1496. DOI:<a href=&quot;https://doi.org/10.1211/00223570272&quot;>10.1211/00223570272</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12495551/&quot;>https://pubmed.ncbi.nlm.nih.gov/12495551</a></p></li><li><p>Dolman, ME, et al., &amp; Kok, RJ (2012). Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 157(3) 461–468. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2011.08.041&quot;>10.1016/j.jconrel.2011.08.041</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21911014/&quot;>https://pubmed.ncbi.nlm.nih.gov/21911014</a></p></li><li><p>Ronca, F, et al., &amp; Ronca, G (1998). Anti-inflammatory activity of chondroitin sulfate. <i>Osteoarthritis and cartilage</i> 6 Suppl A 14–21. DOI:<a href=&quot;https://doi.org/10.1016/s1063-4584(98)80006-x&quot;>10.1016/s1063-4584(98)80006-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9743814/&quot;>https://pubmed.ncbi.nlm.nih.gov/9743814</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Lysozyme;
